Business Case Studies, Mergers, Acquisitions and Takeovers Case Study, Daiichi’s Acquisition of Ranbaxy

print page
Tell A Friend
Bookmark
 

Case Categories

Mergers, Acquisitions and Takeovers Case Study

IBS CDC IBS CDC IBS CDC IBS CDC RSS Feed
Case Title:

Daiichi’s Acquisition of Ranbaxy

Publication Year : 2009

Authors: Bhaskar Mutyala and K Sarat Verma

Industry: Health Care

Region:Global

Case Code: MAA0166

Teaching Note: Available

Structured Assignment: Not Available

Buy This Case Study
OR





Abstract:
On June 11th 2008 Japan’s third largest drug maker Daiichi Sankyo announced, its strategic deal to acquire majority stake in the Indian generic drug major, Ranbaxy Laboratories Limited. Daiichi agreed to pay around US$4.2 billion for acquiring 51% stake (including promoter stake of 34.83%) in Ranbaxy, putting the total enterprise value of Ranbaxy at US$8.5 billion. Daiichi-Ranbaxy deal was the largest acquisition in the Indian pharmaceutical industry and was viewed by analysts as a step towards the consolidation in the world generic drug market. The deal made Daiichi-Ranbaxy, the combined entity the 15th largest pharmaceutical company in the world with a market capitalization of around US$30 billion. It helped Daiichi leverage its innovative drug making capabilities and R&D expertise with Ranbaxy’s low cost manufacturing abilities to achieve a competitive position in the world generic drug market. Some industry experts’ claimed that the price Daiichi paid for acquisition was quite high compared to the present pricing of other Indian generic drug making companies.

Pedagogical Objectives:

  • An in-depth knowledge about DCF valuation techniques
  • The rationale behind the acquisition of Ranbaxy by Daiichi
  • Long-term synergies arising for Ranbaxy after Daiichi acquired it
  • The advantages and disadvantages of M&A deals
  • The need for growth through acquisitions in foreign countries
  • The consolidation trends in the Indian and Global Pharma Industries.

Keywords : Mergers and Acquisitions, DCf Valuation, Pharmaceuticals Industries, Generic Drugs, Synergies, Strategy, Industry value Chain, Daiichi Sankyo, Ranbaxy, Competitive Anaysis, Open Offer, Financial Forecasting

Contents : 
Sankyo Company Limited
Daiichi Pharmaceutical Company
Financing the Deal and Integration
The Spectrum of Activities of Ranbaxy
The Road Ahead
Ranbaxy – Consolidated Income Statement
Ranbaxy – Consolidated Balance Sheet
Overview of World Generic Market
Indian Pharmaceutical Industry
Market Size and Growth over Last 3 Years
Top 25 Pharmaceutical Companies in the World

Recently Bought Case Studies

    Recently Bought Case Studies
advertisement

    Executive Interviews

  • Dr James O` TooleDr James O` Toole

    Dr James O` Toole, Daniels Distinguished Professor of Business Ethics at the University of Denver’s Daniels College of Business
    Speaks on The Making of a CEO
  • Paul BrackenPaul Bracken

    Prof. Paul Bracken, leading expert in global competition and the strategic application of technology in business and defense.
    Speaks on Midlife Crisis
  • Bill FischerBill Fischer

    Bill Fischer, Professor of Technology, IMD
    Speaks on Building High Performance Teams
  • View All Executive Interviews»






Contact us: IBS Case Development Centre (IBSCDC), IFHE Campus, Donthanapally, Sankarapally Road, Hyderabad-501 504, Andhra Pradesh, INDIA.
Mob: +91- 9640901313, Phone: +91 - 08417 - 236672, Fax : + 91 - 08417 - 236674
E-mail: casehelpdesk@ibsindia.org

©2003-2010 IBS Case Development Centre. All rights reserved. | Careers | Privacy Policy | Terms of Use | Disclosure | Site Map xml sitemap